VEGFA and myeloid sarcoma: Patients with SP-MS had significantly higher circulating levels of the vascular epidermal growth factor (VEGF) than all the patients with RR-MS (32±28 vs 15±9, p = 0.0004) and than healthy controls (32±28 vs 21±11, p = 0.04) (Fig 4).